3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
15
Gastrointestinal
4
Thoracic
3
Breast
3
Plasma cell
2
Other hematologic neoplasm
2
Myeloid
2
Lymphoid
2
Gynecologic
2
Other solid neoplasm
1
Head & Neck
1
Dermatologic
1
Classical hematology
1
CNS
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Melanoma
1
Carcinoma, Small Cell
1
Carcinoma, Non-Small-Cell Lung
1
Anus Neoplasms
1
Interventions
pembrolizumab
58
Ipilimumab
53
Cyclophosphamide
53
Nivolumab
45
aldesleukin
35
Interleukin-2
26
fludarabine phosphate
22
fludarabine
21
Vemurafenib
20
Temozolomide
19
Radiotherapy
19
dabrafenib
15
trametinib
12
Radiosurgery
11
CTLA-4 Antigen
11
spartalizumab
10
Filgrastim
10
Dacarbazine
10
cobimetinib
9
binimetinib
9
atezolizumab
9
Biopsy
9
poly ICLC
8
Paclitaxel
8
Antilymphocyte Serum
8
encorafenib
7
avelumab
7
Rituximab
7
Introns
7
romidepsin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
abiraterone
×
Dermatologic
×
Clear all
NCT05551117
2026-02-09
Tamarack
MacroGenics
Phase 2
Terminated
192 enrolled
20 charts